Development of disease-modifying
treatments for rheumatoid arthritisResults
The project has had three main results: Patient selection:
The project has identified means to select patients with a significant response to the substances based on a small blood sample. In generating these data, it was possible to demonstrate that lesion biopsy was not necessary to obtain this information thus potentially sparing intrusive examinations.
Candidate selection:
The project identified a type of macrocyclic substance and has demonstrated its utility for inflammatory bowel disease. If we can progress this substance to the clinic, it should offer a much greater ratio of benefit to side effects relative to many other current treatments.Novel Indications:
As part of the project, we surveyed rare diseases for the involvement of the kinase enzymes that we are focused on . In this process we observed that the most severe form of Rheumatoid arthritis appear to be more relevant than the milder forms previously investigated. Similarly, the serious disease glomerulanephritis appears to depend on specific kinase enzymes and is thus also a potentially important use of the substances.
Publications of the project:
[PDF documents]
[external links]
[4] Development of disease-modifying treatments for rheumatoid arthritis
[5] Human Single-Chain Variable Fragment That Specifically Targets Arthritic Cartilage